ストックスクリーナーアプリを入手
7.17
0.70%
0.05
アフターアワーズ：
7.17
Unicycive Therapeutics Inc (UNCY) 最新ニュース
[EFFECT] Unicycive Therapeutics, Inc. SEC Filing - Stock Titan
Unicycive (NASDAQ: UNCY) CEO receives 762,200 restricted stock units - Stock Titan
Unicycive Therapeutics (UNCY) director receives sizeable new RSU awards - Stock Titan
Director Laumas receives new RSU awards at Unicycive (NASDAQ: UNCY) - Stock Titan
Executive at Unicycive (UNCY) granted 169,500 restricted stock units - Stock Titan
Unicycive Therapeutics (UNCY) CFO awarded 169,500 RSUs as stock compensation - Stock Titan
Unicycive Therapeutics (UNCY) EVP receives 169,500 RSU equity award - Stock Titan
Number of shareholders of Unicycive Therapeutics, Inc. – NASDAQ:UNCY - TradingView
UNCY Q1 2026 Earnings: Wider-Than-Expected Loss Amid No Revenue, Shares SlipEarnings Acceleration Picks - newsline.com
Will Unicycive's OLC Clear The FDA Hurdle And Become An Attractive New Option For Hyperphosphatemia? - RTTNews
Hyperphosphatemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Ardelyx, Sanofi, Takeda Pharma, Unicycive Therapeutics, Taisho Pharma, Alebund Pharma - Barchart.com
Hyperphosphatemia Market Unlocking New Revenue Opportunities - openPR.com
Unicycive Expands At-The-Market Equity Offering Program - The Globe and Mail
Unicycive Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Unicycive Therapeutics Raises ATM Offering of Shares - Moomoo
Unicycive (NASDAQ: UNCY) boosts ATM capacity, files $50M S-3 shelf - Stock Titan
Unicycive Therapeutics (UNCY) registers $150M shelf; $50M ATM with Guggenheim - Stock Titan
Unicycive Therapeutics director Gaurav Aggarwal resigns from board By Investing.com - Investing.com Australia
Unicycive shares edge up as biotech looks to June FDA meeting and analyst lifts target - Bez Kabli
Unicycive Therapeutics director Gaurav Aggarwal resigns from board - Investing.com
UNCY Q1 2026 Earnings: Pre‑Revenue Biotech Reports Wider‑Than‑Expected Loss, Stock Edges Higher - newsline.com
UNCY Maintained by Benchmark -- Price Target Raised to $18.00 - GuruFocus
Benchmark raises Unicycive Therapeutics price target on FDA review By Investing.com - Investing.com Canada
Interview: Unicycive’s CEO on Biotech Innovation vs. Payer Reality - NAVLIN DAILY
UNCY: Upcoming Virtual Meeting Announced for May 29 - GuruFocus
H.C. Wainwright reiterates Unicycive stock rating on manufacturing progress By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Unicycive stock rating on manufacturing progress - Investing.com
Unicycive Therapeutics (UNCY) Edges Higher as Stock Tests Key Resistance Near $7.46Wide Range Bar - newsline.com
Unicycive Therapeutics Inc. (UNCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Unicycive Therapeutics (UNCY) Surges 5.9% as Shares Test Key ResistancePairs Trade - Newser
Unicycive Therapeutics (UNCY) CEO receives 762,200 restricted stock units award - Stock Titan
Unicycive Therapeutics (UNCY) director granted 126,300 RSUs as equity pay - Stock Titan
Unicycive CEO left clinical medicine to develop kidney disease therapies - The Business Journals
Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside - Seeking Alpha
Unicycive (NASDAQ: UNCY) EVP receives 169,500 RSUs as stock award - Stock Titan
Unicycive (UNCY) EVP receives 169,500 RSUs vesting over 3 years - Stock Titan
Unicycive (UNCY) CFO receives 169,500 restricted stock units as equity pay - Stock Titan
Unicycive Therapeutics (UNCY) Drops -4.29% — Key Support at $7.41 2026-05-19Risk Analysis - Newser
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Unicycive Therapeutics (UNCY) price target decreased by 23.53% to 32.20 - MSN
Unicycive (UNCY) director Sandeep Laumas granted two new RSU awards - Stock Titan
RA Capital affiliates hold 2.80M shares in Unicycive (UNCY) under 9.99% blocker - Stock Titan
TradingKey - TradingKey
Unicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing? - Yahoo Finance
Unicycive Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Noble Financial Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Guggenheim lowers Unicycive stock price target on higher costs By Investing.com - Investing.com Canada
Guggenheim Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
Unicycive Therapeutics stock (US90467V1098): Q1 2026 results and PDUFA update - AD HOC NEWS
Unicycive Therapeutics Reports Q1 2026 Financial Results, FDA Review Progress for Oxylanthanum Carbonate NDA, and Commercial Launch Preparations - Minichart
Unicycive Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Unicycive (NASDAQ: UNCY) Q1 2026 loss deepens as warrant liability swings - Stock Titan
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):